CClinicalTrials.gg
CompletedNCT07436273Updated Feb 27, 2026

Development and Validation of a Risk Prediction Model for New-Onset Diabetes After Pancreatectomy

An observational study in Identification of Influencing Factors and Construction of a Prediction Model for New-Onset Diabetes After Pancreatectomy, sponsored by Ningbo No. 1 Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Ningbo No. 1 Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
575
Ages
18 Years and older
Sex
All
01

Study summary

New-onset diabetes is one of the major complications after pancreatectomy. Without timely diagnosis, treatment and management, it can lead to adverse outcomes such as cardiovascular and cerebrovascular events and severe infections, increasing mortality. Moving the management threshold forward, early risk identification, and precise and effective intervention are the keys to its management.

Existing risk prediction studies show high heterogeneity across different populations and surgical procedures. Risk factors available for early identification remain unclear, and most included factors are non-interventional. There are limitations in study design, modeling and validation methods, and the research results provide limited value for guiding risk prediction, prevention and management.

This study adopts a mixed-methods design. We retrospectively analyze the general and clinical data of patients who underwent pancreatectomy at two institutions, follow up the subjects to determine the incidence of postoperative diabetes and postoperative self-management status, and use regression analysis to identify independent risk factors for new-onset diabetes after surgery.

We separately establish a nomogram model, a random forest model, and a deep learning model, perform internal and external validation, compare the performance of the three models, and select the model with optimal clinical performance. Based on the prediction model and evidence-based medicine, we formulate intervention strategies, evaluate their feasibility through clinical trials, refine the intervention items, and finally establish a precise intervention strategy for new-onset diabetes after pancreatectomy to achieve comprehensive, dynamic, efficient and precise management.

Implementation of this project can reduce the incidence and slow the progression of diabetes after pancreatectomy, improve clinical outcomes, lower readmission and mortality rates, save social medical resources, and provide decision-making guidance and practical evidence for the prevention and control of chronic diseases.

02

Conditions studied

  • Identification of Influencing Factors and Construction of a Prediction Model for New-Onset Diabetes After Pancreatectomy
03

In context

Lead sponsor

Ningbo No. 1 Hospital is the lead sponsor of 56 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients after pancreatectomy

Inclusion criteria

  1. Patients undergoing pancreatectomy via open, laparoscopic, or robot-assisted approach.
  2. Age ≥ 18 years.

Exclusion criteria

Exclusion Criteria:

  1. Patients who underwent total pancreatectomy.
  2. Patients with a preoperative diagnosis of diabetes.
  3. Patients with incomplete clinical or follow-up data.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
575 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherNo Biologics

    Observational Study

06

What researchers measure

Primary outcomes

  1. Whether new-onset diabetes occurred

    Time frame: 12months

07

Study locations

1 site
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang 312000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436273
Lead sponsor
Ningbo No. 1 Hospital
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Jun 1, 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion